The oncology market has witnessed a sizeable shift of focus away from cytotoxic therapies and antihormonal therapies towards the more lucrative targeted therapies and immunotherapies class in the last decade. This class boasts several of the top-selling anticancer brands overall, and has fueled most of the recent rapid growth of the oncology market as a whole.

Between 2010 and 2019, conditions in the oncology market will support relatively high growth rates for the targeted therapies and immunotherapies currently on the market. Combined sales in this class will grow at a CAGR of 6.6 % from $19.5 billion in 2009 to reach $36.8 billion in 2019.

Avastin (bevacizumab; Roche/Chugai) was the leading oncology brand in 2009. Despite a number of setbacks (including failures in Phase III trials in certain new indications) and potential threats, sales of Avastin will continue to grow, driven by further indication expansions and increasing uptake in existing indications and new territories.

With a dominant presence in three of the four highest incidence solid tumors and the highest incidence hematological malignancy, Roche dominates the cancer targeted therapies and immunotherapies market. This will continue through to 2019, driven by the strong performance of the company’s monoclonal antibody franchise.

This report covers:

• The performance of each of the marketed cancer targeted therapies and immunotherapies in the seven major markets over the period 2009 to 2019

• The changing key opportunities and threats both for currently marketed and pipeline targeted therapy and immunotherapy brands

• The leading brands in this market over the next 10 years and the key factors driving their success

For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2801270

Contact:

Veronica Franco

MarketResearch.com

vfranco@marketresearch.com

240.747.3016